127 related articles for article (PubMed ID: 14656624)
1. Imatinib-associated pulmonary alveolar proteinosis.
Wagner U; Staats P; Moll R; Feek U; Vogelmeier C; Groneberg DA
Am J Med; 2003 Dec; 115(8):674. PubMed ID: 14656624
[No Abstract] [Full Text] [Related]
2. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
[No Abstract] [Full Text] [Related]
3. Hypersensitivity pneumonitis related to imatinib mesylate.
Bergeron A; Bergot E; Vilela G; Ades L; Devergie A; Espérou H; Socié G; Calvo F; Gluckman E; Ribaud P; Rousselot P; Tazi A
J Clin Oncol; 2002 Oct; 20(20):4271-2. PubMed ID: 12377975
[No Abstract] [Full Text] [Related]
4. Imatinib mesylate induced immune thrombocytopenia.
Rajappa S; Varadpande L; Paul TR; Digumarti R
Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
[No Abstract] [Full Text] [Related]
5. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
[No Abstract] [Full Text] [Related]
6. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
Ramar K; Potti A; Mehdi SA
J Clin Oncol; 2003 Jan; 21(1):172-3. PubMed ID: 12506189
[No Abstract] [Full Text] [Related]
7. Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.
Mabed M; Elhefni AM; Damnhouri G
Leuk Lymphoma; 2012 Nov; 53(11):2310-1. PubMed ID: 22462614
[No Abstract] [Full Text] [Related]
8. Precipitation of porphyria cutanea tarda by imatinib mesylate?
Ho AY; Deacon A; Osborne G; Mufti GJ
Br J Haematol; 2003 Apr; 121(2):375. PubMed ID: 12694262
[No Abstract] [Full Text] [Related]
9. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
[No Abstract] [Full Text] [Related]
10. Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
Machaczka M; Gossart M
Pol Arch Med Wewn; 2013; 123(5):251-2. PubMed ID: 23722191
[No Abstract] [Full Text] [Related]
11. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia.
Prabhash K; Biswas G; Prasad N; Karant N; Sastry PS; Parikh PM
Indian J Dermatol Venereol Leprol; 2006; 72(1):63-4. PubMed ID: 16481719
[No Abstract] [Full Text] [Related]
12. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
Ostro D; Lipton J
Leuk Lymphoma; 2007 Jan; 48(1):195-6. PubMed ID: 17325868
[No Abstract] [Full Text] [Related]
13. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
Lau YM; Lam YK; Leung KH; Lin SY
Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
[No Abstract] [Full Text] [Related]
14. Imatinib mesylate.
Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
[No Abstract] [Full Text] [Related]
15. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
[No Abstract] [Full Text] [Related]
16. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571.
Kitiyakara C; Atichartakarn V
Nephrol Dial Transplant; 2002 Apr; 17(4):685-7. PubMed ID: 11917072
[No Abstract] [Full Text] [Related]
17. [Imatinib mesylate-induced acute cytolytic hepatitis].
Rocca P; El Jastimi S; Troncy J; Scoazec JY; Boucher A; Vial T; Trépo C; Zoulim F
Gastroenterol Clin Biol; 2004 Oct; 28(10 Pt 1):918-9. PubMed ID: 15523233
[No Abstract] [Full Text] [Related]
18. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.
Rajda J; Phatak PD
Am J Hematol; 2005 May; 79(1):80-1. PubMed ID: 15849772
[No Abstract] [Full Text] [Related]
19. Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate.
Pasmatzi E; Monastirli A; Matsouka P; Tsambaos D
Acta Derm Venereol; 2003; 83(5):391-2. PubMed ID: 14609118
[No Abstract] [Full Text] [Related]
20. Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
Raanani P; Goldman JM; Ben-Bassat I
J Clin Oncol; 2002 Feb; 20(3):869-70. PubMed ID: 11821474
[No Abstract] [Full Text] [Related]
[Next] [New Search]